Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Antimicrob Chemother ; 62(3): 539-42, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18544603

ABSTRACT

OBJECTIVES: Voriconazole and posaconazole are effective as both prophylaxis and treatment for invasive aspergillosis (IA) in immunocompromised patients. Hence, it is important to determine whether Aspergillus pre-exposure to voriconazole or posaconazole diminishes subsequent posaconazole or voriconazole activity, respectively. METHODS: We used Aspergillus fumigatus (AF) 293 conidia with or without prior exposure to voriconazole or posaconazole [three serial passages on plates containing regular yeast extract-glucose (YAG) media, YAG+0.0625 mg/L voriconazole or YAG+0.025 mg/L posaconazole]. Toll-deficient Drosophila melanogaster flies were infected by injection, and 8 day survival was monitored. Following infection, flies were fed either regular food, food containing 1000 mg/L voriconazole (posaconazole-exposed conidia) or 1000 mg/L posaconazole (voriconazole-exposed conidia). Voriconazole and posaconazole concentrations in flies were confirmed by HPLC. RESULTS: AF inoculation resulted in 71% mortality 8 days post-infection (median survival 4 days). Prior conidial exposure to voriconazole or posaconazole did not affect mortality (73%, P = 0.8 for voriconazole pre-exposed and 76%, P = 0.49 for posaconazole pre-exposed). Voriconazole treatment post-infection had a protective effect, reducing mortality to 42% (P = 0.0002), while prior conidial exposure to posaconazole did not alter the protective effect of voriconazole (34% 8 day mortality, P = 0.35). Likewise, posaconazole treatment post-infection reduced mortality to 36%, while prior conidial exposure to voriconazole did not alter the protective effect of posaconazole (39% mortality, P = 0.92). Median fly homogenate concentrations of voriconazole and posaconazole were 0.44 and 2.05 mg/L, respectively. CONCLUSIONS: Prior exposure of AF to voriconazole or posaconazole did not affect the virulence of AF nor the subsequent activity of the alternate triazole in a Drosophila model of IA.


Subject(s)
Antifungal Agents/pharmacology , Aspergillus fumigatus/drug effects , Pyrimidines/pharmacology , Pyrimidines/therapeutic use , Triazoles/pharmacology , Triazoles/therapeutic use , Animals , Aspergillosis/microbiology , Drosophila Proteins/deficiency , Drosophila melanogaster , Survival Analysis , Toll-Like Receptors/deficiency , Virulence/drug effects , Voriconazole
2.
Eur J Clin Microbiol Infect Dis ; 27(5): 343-7, 2008 May.
Article in English | MEDLINE | ID: mdl-18183439

ABSTRACT

Few data exist on the etiology, presentation, prognosis, and management of fungal endophthalmitis (FE) in cancer patients. FE cases were identified by reviewing the ophthalmology reports and microbiology cultures of patients at The University of Texas M. D. Anderson Cancer Center. We retrospectively reviewed the medical records and obtained information related to malignancy, fungal infection and its management, visual outcome, and mortality. We compared FE caused by Candida spp. (CE) to FE caused by molds (ME). Of the 102 cancer patients with a fungal infection for whom an ophthalmology consult was requested, 23 met the criteria for definite (N = 6) or probable (N = 17) FE (8 with CE, 15 with ME). All of the patients with ME had hematologic malignancies, whereas half of the patients with CE had solid tumor (P = .008). Only patients with CE had a history of surgery within 30 days of FE diagnosis (38%, P = .03). Fungal pneumonia [17 (74%)] and disseminated infection [14, (61%)] were common. The most common presenting symptoms were decreased vision [16 (70%)] and ocular pain [14 (61%)]. All treated patients received systemic antifungals (combination therapy in 72% of the cases). Seven patients (30%) underwent vitrectomy. Only one patient received intraocular injection of amphotericin B along with systemic antifungals. Four-week mortality was high [13 (57%)], especially in ME (73%, P = .04). Among the eight surviving patients where visual acuity could be assessed, visual outcome improved or remained stable in five (63%). FE in cancer patients occurs in the setting of severe, frequently disseminated opportunistic mycoses, is caused predominantly by hyalohyphomycetes, and is a marker for high 4-week mortality.


Subject(s)
Endophthalmitis/microbiology , Mycoses/diagnosis , Neoplasms/complications , Adult , Aged , Antifungal Agents/therapeutic use , Candida/isolation & purification , Endophthalmitis/mortality , Endophthalmitis/physiopathology , Endophthalmitis/therapy , Female , Fungi/isolation & purification , Hospitals , Humans , Male , Middle Aged , Mycoses/mortality , Mycoses/physiopathology , Mycoses/therapy , Pneumonia/microbiology , Postoperative Complications , Retrospective Studies , Risk Factors , Texas , Vitrectomy
3.
Antimicrob Agents Chemother ; 52(2): 722-4, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18025115

ABSTRACT

Human polymorphonuclear neutrophils (HPMNs) displayed attenuated hyphal damage associated with impaired O(2)(-) release following exposure to Rhizopus oryzae versus that with Aspergillus fumigatus. Exposure of HPMNs to R. oryzae hyphae resulted in upregulation in Toll-like receptor 2 mRNA and a robust proinflammatory gene expression with rapid (1-h) induction of NF-kappaB pathway-related genes.


Subject(s)
Hyphae/immunology , Inflammation/immunology , Neutrophils/immunology , Rhizopus/immunology , Toll-Like Receptor 2/metabolism , Up-Regulation , Aspergillus fumigatus/growth & development , Aspergillus fumigatus/immunology , Humans , Lectins, C-Type , Membrane Proteins/metabolism , NF-kappa B/metabolism , Nerve Tissue Proteins/metabolism , Oxidative Stress , Rhizopus/growth & development , Superoxides/metabolism , Toll-Like Receptor 2/genetics
4.
Med Mycol ; 44(2): 193-6, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16519024

ABSTRACT

Crl:CDI(ICR) BR adult mice were fed chow containing Candida albicans or regular chow. Both groups were subsequently given either antibiotics acting mainly against Gram-positive organisms or normal saline for 10 days. Stool cultures were performed before, at the end, and one week after discontinuation of treatment to determine the effects on the stool yeast concentration. Candida colonized mice treated with vancomycin, teicoplanin, linezolid, quinupristin-dalfopristin or telithromycin had higher colony counts of yeast in their stools than control Candida fed mice treated with saline. This increase was not statistically significant. Mice fed regular chow treated with the study drugs or saline did not have any yeasts in their stools. Dissemination of Candida was not observed in the visceral organs of any mouse.


Subject(s)
Anti-Bacterial Agents/adverse effects , Candida albicans/growth & development , Candidiasis/microbiology , Gastrointestinal Diseases/microbiology , Animals , Feces/microbiology , Mice , Mice, Inbred ICR
SELECTION OF CITATIONS
SEARCH DETAIL
...